Cancer disease progression and death during the COVID-19 pandemic: a multidisciplinary analysis for the Peruvian setting.

Since the COVID-19 pandemic began in China in late 2019, infection from the SARS-CoV-2 virus has spread virtually worldwide. This infection has adversely affected several countries; governments have outlined a series of political measures aimed to preserve the health and safety of their populations. In Peru, most actions have prioritised COVID-19 attention, with a subsequent gap in the healthcare facilities needed for other diseases. Cancer, one principal cause of death in the country, is usually diagnosed late. Moreover, in the pandemic context, the prevention and control of cancer have been negatively affected. Therefore, we carried out a multidisciplinary analysis using the Ishikawa diagram to identify the probable factors that contribute to cancer progression and deaths in Peru.

Consenso peruano de diagnóstico y tratamiento de la micosis fungoides y síndrome de Sezary / A peruvian consensus for the diagnosis and therapy of mycosis fungoides and Sézary

Introducción: varias revisiones y guías de manejo de Micosis Fungoides (MF) y Síndrome Sézary (SS) han sido publicados. Sin embargo, estrategias terapeúticas para esta entidad varían entre instituciones y países. Existen pocos estudios fase III que permitan tomar decisiones en el tratamiento de MF/SS. Por tanto éste es frecuentemente determinado por las experiencias institucionales. Objetivo: con el objeto de sumarizar la evidencia disponible y revisar las mejores prácticas, es que se realizó un Consenso Peruano llevado a caboen Setiembre 2008 para establecer guías de diagnóstico y tratamientode MF/SS. Resultados: este artículo revisa los criterios clínicos, histopatológicos y terapéuticos de MF/SS.

Background: Several reviews and guidelines on the management of Mycosis Fungoides (MF) and Sézary syndrome (SS) have been published; however, treatment strategies for patients with MF/SS vary from institution to institution and among countries. There are few phase III trials to support treatment decisions for MF/SS and treatment is often determined by institutional experience. Objetive: In order to summarise the available evidence and reviewbest practices, Peruvian Consensus met in September 2004 to establish guidelines for the diagnosis and treatment of MF/SS. Results: This article reviews hystopatologic, clinic and therapeutic criteria of MF/SS.